PLoS Medicine, 2022 BackgroundEarly antiviral treatment is effective for Coronavirus Disease 2019 (COVID-19) but currently available agents are expensive. Favipiravir is routinely used in many countries, but efficacy is unproven.
David M Lowe +18 more
doaj +1 more source
Repurposing Interleukin-6 Inhibitors to Combat COVID-19. [PDF]
, 2020 Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications across the world. One of the most frequent causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus disease 2019 (COVID-19), which is associated
Kato, Shumei, Kurzrock, Razelle
core +1 more source
Determination of Favipiravir in Human Blood Plasma by HPLC-MS/MS
Разработка и регистрация лекарственных средств, 2023 Introduction. Favipiravir is one of the most well-known broad-spectrum drugs against many RNA viruses, including the severe acute respiratory syndrome virus 2 [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)].
T. N. Komarov +8 more
doaj +1 more source
Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. [PDF]
, 2016 BACKGROUND: By January, 2016, all known transmission chains of the Ebola virus disease (EVD) outbreak in west Africa had been stopped. However, there is concern about persistence of Ebola virus in the reproductive tract of men who have survived EVD.
Anglaret, Xavier +40 more
core +4 more sources
Advances towards norovirus antivirals [PDF]
, 2016 Human noroviruses are a leading cause of gastroenteritis worldwide, yet there are no licensed antivirals. There is an urgent need for norovirus therapeutics, particularly for chronic infections in immunocompromised individuals, but also a potential need ...
Arias, Armando +2 more
core +1 more source
Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. [PDF]
PLoS Neglected Tropical Diseases, 2013 Junín virus (JUNV), the etiologic agent of Argentine hemorrhagic fever (AHF), is classified by the NIAID and CDC as a Category A priority pathogen. Presently, antiviral therapy for AHF is limited to immune plasma, which is readily available only in the ...
Brian B Gowen +11 more
doaj +1 more source
Ebola Virus Infection: a review on the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials [PDF]
, 2016 International audienceThe 2014-2015 outbreak of Ebola virus disease (EVD) is the largest epidemic to date in terms of number of cases, of death and affected areas. In October 2015, no antiviral agents had proven an antiviral efficacy in patients. However
De Lamballerie, Xavier +6 more
core +3 more sources
JIIS: Jurnal Ilmiah Ibnu Sina, 2023 Favipiravir merupakan antivirus untuk pengobatan COVID-19 karena mekanisme kerja obat atau efektivitasnya yang baik pada pasien COVID-19 dengan atau tanpa pneumonia.
Rika Yulia +4 more
doaj +1 more source
Broad Spectrum Antiviral Activity of Favipiravir (T-705): Protection from Highly Lethal Inhalational Rift Valley Fever [PDF]
, 2014 Background:Development of antiviral drugs that have broad-spectrum activity against a number of viral infections would be of significant benefit.
AI Al-Afaleq +55 more
core +2 more sources
Norovirus Polymerase Fidelity Contributes to Viral Transmission In Vivo. [PDF]
, 2016 Intrahost genetic diversity and replication error rates are intricately linked to RNA virus pathogenesis, with alterations in viral polymerase fidelity typically leading to attenuation during infections in vivo.
Armando Arias +5 more
core +5 more sources